Literature DB >> 24395615

The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Byron P Vaughn1, Sveta Shah, Adam S Cheifetz.   

Abstract

OPINION STATEMENT: Mucosal healing is a promising therapeutic endpoint in the treatment of inflammatory bowel disease. Currently, the treatment of IBD focuses predominantly on clinical remission, without requiring a demonstration of mucosal healing. However, recent studies suggest that achieving mucosal healing engenders better outcomes. In this review, we will examine the concept of mucosal healing, including its definitions and assessment techniques, and will evaluate the data regarding the potential benefits of achieving mucosal healing in the treatment of IBD. Furthermore, we will discuss how often mucosal healing can be expected with each of the therapies for IBD. While achieving mucosal healing is an ideal outcome, it may not be practical or feasible in any given patient. Although we suggest that mucosal healing be discussed with all patients, the practicing physician should realize that this goal may not be possible and should manage the patient accordingly.

Entities:  

Year:  2014        PMID: 24395615      PMCID: PMC3938312          DOI: 10.1007/s11938-013-0008-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  75 in total

1.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

Review 2.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

3.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

4.  Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors:  Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

5.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

6.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

7.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 8.  Review article: Crohn's disease: monitoring disease activity.

Authors:  R Sostegni; M Daperno; N Scaglione; A Lavagna; R Rocca; A Pera
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

9.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.

Authors:  Atsushi Sakuraba; Maria L Annunziata; Russell D Cohen; Stephen B Hanauer; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

View more
  13 in total

1.  Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  J Crohns Colitis       Date:  2016-02-13       Impact factor: 9.071

2.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) activation contributes to the pathogenesis of experimental colitis via inhibition of intestinal epithelial cell proliferation.

Authors:  Kellie E Cunningham; Elizabeth A Novak; Garret Vincent; Vei Shaun Siow; Brian D Griffith; Sarangarajan Ranganathan; Matthew R Rosengart; Jon D Piganelli; Kevin P Mollen
Journal:  FASEB J       Date:  2018-08-16       Impact factor: 5.191

3.  Antiinflammatory effect of phytosterols in experimental murine colitis model: prevention, induction, remission study.

Authors:  Rita Aldini; Matteo Micucci; Monica Cevenini; Romana Fato; Christian Bergamini; Cristina Nanni; Massimiliano Cont; Cecilia Camborata; Silvia Spinozzi; Marco Montagnani; Giulia Roda; Antonia D'Errico-Grigioni; Francesca Rosini; Aldo Roda; Giuseppe Mazzella; Alberto Chiarini; Roberta Budriesi
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 4.  Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.

Authors:  Nayara Braga Emidio; Stuart M Brierley; Christina I Schroeder; Markus Muttenthaler
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-09

5.  Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.

Authors:  K J Baldauf; J M Royal; J C Kouokam; B Haribabu; V R Jala; K Yaddanapudi; K T Hamorsky; G W Dryden; N Matoba
Journal:  Mucosal Immunol       Date:  2016-11-02       Impact factor: 7.313

6.  A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repair via an unfolded protein response.

Authors:  Joshua M Royal; Young Jun Oh; Michael J Grey; Wayne I Lencer; Nemencio Ronquillo; Susan Galandiuk; Nobuyuki Matoba
Journal:  FASEB J       Date:  2019-09-27       Impact factor: 5.834

Review 7.  The current and future role of endomicroscopy in the management of inflammatory bowel disease.

Authors:  Douglas L Nguyen; John G Lee; Nimisha K Parekh; Jason Samarasena; Matthew L Bechtold; Kenneth Chang
Journal:  Ann Gastroenterol       Date:  2015 Jul-Sep

8.  Fecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation.

Authors:  Edgar S Wills; Daisy M A E Jonkers; Paul H Savelkoul; Ad A Masclee; Marieke J Pierik; John Penders
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 9.  Intestinal epithelium in inflammatory bowel disease.

Authors:  Mehmet Coskun
Journal:  Front Med (Lausanne)       Date:  2014-08-25

Review 10.  Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa.

Authors:  Joshua M Royal; Nobuyuki Matoba
Journal:  Toxins (Basel)       Date:  2017-11-23       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.